Capri Medical designs implantable bioelectronic neurostimulation devices focused on peripheral nervous system modulation. The company positions its platform around minimally invasive delivery intended to shift neuromodulation out of the operating room and into office-based care.

The system is built around an ultra-miniature, injectable implant with hermetic sealing and an anti-migration design, using wireless power and external control. Capri Medical describes an architecture that pairs the implant with a controller and software layer to deliver programmable stimulation while keeping the implant footprint small enough for injection-based placement.

The company’s disclosed clinical direction includes chronic migraine and chronic peripheral nerve pain, with the broader platform framed as multi-indication neuromodulation. Capri Medical positions itself as a next-generation neurostimulation developer aiming to expand access by simplifying implantation and deployment pathways.